MCID: DFF036
MIFTS: 51

Differentiated Thyroid Carcinoma

Categories: Cancer diseases, Endocrine diseases, Rare diseases

Aliases & Classifications for Differentiated Thyroid Carcinoma

MalaCards integrated aliases for Differentiated Thyroid Carcinoma:

Name: Differentiated Thyroid Carcinoma 59
Papillary or Follicular Thyroid Carcinoma 59
Differentiated Thyroid Gland Carcinoma 73
Well-Differentiated Thyroid Carcinoma 59

Characteristics:

Orphanet epidemiological data:

59
differentiated thyroid carcinoma
Inheritance: Not applicable; Prevalence: 1-9/100000 (Worldwide),1-9/100000 (Europe); Age of onset: Adult;

Classifications:

Orphanet: 59  
Rare endocrine diseases


External Ids:

Orphanet 59 ORPHA146
ICD10 via Orphanet 34 C73
UMLS via Orphanet 74 C0238463
UMLS 73 C1337013

Summaries for Differentiated Thyroid Carcinoma

MalaCards based summary : Differentiated Thyroid Carcinoma, also known as papillary or follicular thyroid carcinoma, is related to thyroid cancer and thyroid cancer, nonmedullary, 1. An important gene associated with Differentiated Thyroid Carcinoma is BRAF (B-Raf Proto-Oncogene, Serine/Threonine Kinase), and among its related pathways/superpathways are Nanog in Mammalian ESC Pluripotency and Phospholipase-C Pathway. The drugs Nexavar and Lenvatinib have been mentioned in the context of this disorder. Affiliated tissues include thyroid, bone and lymph node, and related phenotypes are Decreased viability and Decreased viability

Related Diseases for Differentiated Thyroid Carcinoma

Diseases related to Differentiated Thyroid Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 101)
# Related Disease Score Top Affiliating Genes
1 thyroid cancer 30.8 BRAF HRAS KRAS NCOA4 NRAS NTRK1
2 thyroid cancer, nonmedullary, 1 30.5 BRAF GAS8-AS1 NCOA4
3 thyroid cancer, nonmedullary, 2 29.9 BRAF HRAS NRAS PAX8
4 adenocarcinoma 29.8 ALK BRAF HRAS KRAS NTRK3
5 lung cancer susceptibility 3 29.7 ALK BRAF HRAS KRAS NRAS
6 familial papillary or follicular thyroid carcinoma 12.5
7 giant congenital nevus 10.3 HRAS NRAS
8 urachal adenocarcinoma 10.3 BRAF KRAS
9 sigmoid neoplasm 10.3 HRAS KRAS
10 adult mesoblastic nephroma 10.3 ETV6 NTRK3
11 benign struma ovarii 10.3 HRAS NRAS
12 apocrine adenoma 10.3 HRAS KRAS
13 pulmonic stenosis 10.3 BRAF HRAS KRAS
14 ovarian serous cystadenocarcinoma 10.3 BRAF HRAS NRAS
15 malignant struma ovarii 10.3 HRAS NCOA4 NRAS
16 hyperplastic polyposis syndrome 10.3 BRAF KRAS
17 cardiofaciocutaneous syndrome 1 10.3 BRAF HRAS KRAS
18 adult fibrosarcoma 10.3 ETV6 HRAS NTRK3
19 spitz nevus 10.3 BRAF HRAS
20 syringocystadenoma papilliferum 10.3 BRAF KRAS
21 cellular congenital mesoblastic nephroma 10.3 ETV6 NRAS NTRK3
22 congenital mesoblastic nephroma 10.3 ETV6 NRAS NTRK3
23 periampullary adenoma 10.3 HRAS KRAS
24 schimmelpenning-feuerstein-mims syndrome 10.3 HRAS KRAS NRAS
25 papillary carcinoma 10.3 BRAF NCOA4 PAX8
26 colorectal adenocarcinoma 10.3 BRAF HRAS KRAS
27 thyroiditis 10.2
28 paronychia 10.2 HRAS KRAS
29 lung adenoid cystic carcinoma 10.2 ALK HRAS KRAS
30 acneiform dermatitis 10.2 HRAS KRAS NRAS
31 core binding factor acute myeloid leukemia 10.2 HRAS KRAS NRAS
32 pediatric fibrosarcoma 10.2 ETV6 NTRK1 NTRK3
33 liver angiosarcoma 10.2 HRAS KRAS NRAS
34 adenosquamous lung carcinoma 10.2 ALK HRAS KRAS
35 congenital fibrosarcoma 10.2 ETV6 NTRK1 NTRK3
36 ovarian melanoma 10.2 HRAS NRAS
37 nevus, epidermal 10.2 HRAS KRAS NRAS
38 renal cell carcinoma, papillary, 1 10.2 BRAF HRAS NRAS PAX8
39 leukemia, chronic lymphocytic 2 10.2 BRAF HRAS KRAS NRAS
40 malignant ovarian surface epithelial-stromal neoplasm 10.2 HRAS KRAS PAX8
41 ovary epithelial cancer 10.2 HRAS KRAS PAX8
42 autonomic nervous system neoplasm 10.2 ALK NRAS NTRK1
43 peripheral nervous system neoplasm 10.2 ALK NRAS NTRK1
44 respiratory system cancer 10.2 ALK HRAS KRAS
45 bladder urothelial carcinoma 10.2 BRAF HRAS KRAS NRAS
46 hypothyroidism 10.2
47 malignant conjunctival melanoma 10.2 HRAS NRAS
48 bile duct cysts 10.2 HRAS KRAS
49 lung squamous cell carcinoma 10.2 ALK BRAF HRAS KRAS
50 respiratory system disease 10.2 ALK HRAS KRAS

Graphical network of the top 20 diseases related to Differentiated Thyroid Carcinoma:



Diseases related to Differentiated Thyroid Carcinoma

Symptoms & Phenotypes for Differentiated Thyroid Carcinoma

GenomeRNAi Phenotypes related to Differentiated Thyroid Carcinoma according to GeneCards Suite gene sharing:

26 (show all 33)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-2 10.16 BRAF HRAS KRAS TRIM24
2 Decreased viability GR00106-A-0 10.16 KRAS
3 Decreased viability GR00221-A-1 10.16 HRAS KRAS
4 Decreased viability GR00221-A-2 10.16 HRAS KRAS
5 Decreased viability GR00221-A-3 10.16 HRAS
6 Decreased viability GR00221-A-4 10.16 BRAF
7 Decreased viability GR00301-A 10.16 BRAF KRAS
8 Decreased viability GR00381-A-1 10.16 BRAF KRAS TRIM24
9 Decreased viability GR00402-S-2 10.16 BRAF HRAS KRAS TRIM24
10 Decreased cell migration GR00055-A-1 9.8 ALK BRAF HRAS KRAS NTRK1 TRIM24
11 Increased shRNA abundance (Z-score > 2) GR00366-A-110 9.74 BRAF
12 Increased shRNA abundance (Z-score > 2) GR00366-A-120 9.74 NCOA4
13 Increased shRNA abundance (Z-score > 2) GR00366-A-123 9.74 TRIM24
14 Increased shRNA abundance (Z-score > 2) GR00366-A-125 9.74 TRIM24
15 Increased shRNA abundance (Z-score > 2) GR00366-A-127 9.74 TRIM24
16 Increased shRNA abundance (Z-score > 2) GR00366-A-128 9.74 NCOA4
17 Increased shRNA abundance (Z-score > 2) GR00366-A-147 9.74 NCOA4
18 Increased shRNA abundance (Z-score > 2) GR00366-A-149 9.74 BRAF
19 Increased shRNA abundance (Z-score > 2) GR00366-A-159 9.74 NCOA4
20 Increased shRNA abundance (Z-score > 2) GR00366-A-161 9.74 NTRK1
21 Increased shRNA abundance (Z-score > 2) GR00366-A-166 9.74 BRAF
22 Increased shRNA abundance (Z-score > 2) GR00366-A-177 9.74 BRAF
23 Increased shRNA abundance (Z-score > 2) GR00366-A-194 9.74 BRAF
24 Increased shRNA abundance (Z-score > 2) GR00366-A-29 9.74 BRAF
25 Increased shRNA abundance (Z-score > 2) GR00366-A-31 9.74 BRAF
26 Increased shRNA abundance (Z-score > 2) GR00366-A-32 9.74 BRAF
27 Increased shRNA abundance (Z-score > 2) GR00366-A-44 9.74 NCOA4
28 Increased shRNA abundance (Z-score > 2) GR00366-A-47 9.74 BRAF NCOA4 NTRK1 TRIM24
29 Increased shRNA abundance (Z-score > 2) GR00366-A-52 9.74 NTRK1
30 Increased shRNA abundance (Z-score > 2) GR00366-A-63 9.74 NTRK1
31 Increased shRNA abundance (Z-score > 2) GR00366-A-81 9.74 NCOA4
32 Increased shRNA abundance (Z-score > 2) GR00366-A-85 9.74 NTRK1 TRIM24
33 Increased cell migration GR00055-A-3 9.26 BRAF HRAS KRAS TRIM27

MGI Mouse Phenotypes related to Differentiated Thyroid Carcinoma:

46 (show all 11)
# Description MGI Source Accession Score Top Affiliating Genes
1 growth/size/body region MP:0005378 10.25 ALK BRAF ETV6 GOLGA5 HRAS KRAS
2 mortality/aging MP:0010768 10.22 ALK BRAF ERC1 ETV6 GOLGA5 HRAS
3 homeostasis/metabolism MP:0005376 10.18 ALK BRAF ERC1 ETV6 HRAS KRAS
4 embryo MP:0005380 10.11 BRAF ETV6 GOLGA5 KRAS LPAR4 NDUFA13
5 craniofacial MP:0005382 10.04 BRAF GOLGA5 HRAS KRAS LPAR4 NRAS
6 digestive/alimentary MP:0005381 10.02 BRAF ETV6 GOLGA5 HRAS KRAS NRAS
7 integument MP:0010771 9.97 ALK BRAF ETV6 HRAS KRAS LPAR4
8 neoplasm MP:0002006 9.91 ALK BRAF ETV6 HRAS KRAS NRAS
9 no phenotypic analysis MP:0003012 9.76 ERC1 ETV6 HRAS KRAS NRAS NTRK1
10 normal MP:0002873 9.65 BRAF ERC1 ETV6 HRAS KRAS NRAS
11 pigmentation MP:0001186 9.02 ALK BRAF KRAS NRAS NTRK1

Drugs & Therapeutics for Differentiated Thyroid Carcinoma

FDA approved drugs:

# Drug Name Active Ingredient(s) 18 Company Approval Date
1
Nexavar 18 49 SORAFENIB TOSYLATE Bayer/Onyx December 2005

Drugs for Differentiated Thyroid Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 145)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Lenvatinib Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 417716-92-8
2 Protein Kinase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
3
Sorafenib Approved, Investigational Phase 3,Phase 2 284461-73-0 216239 406563
4
Iodine Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 7553-56-2 807
5
Nicotinamide Approved, Investigational Phase 3,Phase 2 98-92-0 936
6
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 2 59-30-3 6037
7
Niacin Approved, Investigational, Nutraceutical Phase 3,Phase 2 59-67-6 938
8 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 3,Phase 2,Phase 1,Not Applicable
9 Hormone Antagonists Phase 3,Phase 2,Phase 1,Not Applicable
10 Hormones Phase 3,Phase 2,Phase 1,Not Applicable
11 Vitamin B Complex Phase 3,Phase 2
12 Trace Elements Phase 3,Phase 2,Phase 1,Not Applicable
13 Vitamins Phase 3,Phase 2,Not Applicable
14 Micronutrients Phase 3,Phase 2,Phase 1,Not Applicable
15 Vitamin B9 Phase 3,Phase 2
16 Folate Phase 3,Phase 2
17 cadexomer iodine Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
18 Anti-Infective Agents Phase 3,Phase 2,Phase 1,Not Applicable
19 Anti-Infective Agents, Local Phase 3,Phase 2,Phase 1,Not Applicable
20 Nicotinic Acids Phase 3,Phase 2
21 Vitamin B3 Phase 3,Phase 2
22
Rosiglitazone Approved, Investigational Phase 2 122320-73-4 77999
23
Somatostatin Approved, Investigational Phase 2 51110-01-1, 38916-34-6 53481605
24
Sunitinib Approved, Investigational Phase 2 557795-19-4, 341031-54-7 5329102
25
Celecoxib Approved, Investigational Phase 2 169590-42-5 2662
26
Capecitabine Approved, Investigational Phase 2 154361-50-9 60953
27
Panobinostat Approved, Investigational Phase 2 404950-80-7 6918837
28
Lithium carbonate Approved Phase 2 554-13-2
29
Valproic Acid Approved, Investigational Phase 2 99-66-1 3121
30
Bortezomib Approved, Investigational Phase 2 179324-69-7 387447 93860
31
Vemurafenib Approved Phase 2,Not Applicable 918504-65-1 23252090 42611257
32
Metformin Approved Phase 2,Not Applicable 657-24-9 14219 4091
33
Dabrafenib Approved, Investigational Phase 2,Not Applicable 1195765-45-7 44462760 44516822
34
Trametinib Approved Phase 2,Phase 1 871700-17-3 11707110
35
Cisplatin Approved Phase 2,Phase 1 15663-27-1 2767 441203 84093
36
Doxorubicin Approved, Investigational Phase 2 23214-92-8 31703
37
Paclitaxel Approved, Vet_approved Phase 2 33069-62-4 36314
38
Bevacizumab Approved, Investigational Phase 2 216974-75-3
39
Atezolizumab Approved, Investigational Phase 2,Phase 1 1380723-44-3
40
Benzocaine Approved, Investigational Phase 2 94-09-7, 1994-09-7 2337
41 tannic acid Approved Phase 2
42
Everolimus Approved Phase 2 159351-69-6 6442177
43
Sirolimus Approved, Investigational Phase 2 53123-88-9 46835353 6436030 5284616
44
Miconazole Approved, Investigational, Vet_approved Phase 2 22916-47-8 4189
45
Cyclophosphamide Approved, Investigational Phase 2 6055-19-2, 50-18-0 2907
46
Radium Ra 223 dichloride Approved, Investigational Phase 2 444811-40-9
47
Pembrolizumab Approved Phase 2 1374853-91-4
48
Salmon Calcitonin Approved, Investigational Phase 2 47931-85-1 16129616
49
Irinotecan Approved, Investigational Phase 1, Phase 2 100286-90-6, 97682-44-5 60838
50
Oxaliplatin Approved, Investigational Phase 1, Phase 2,Phase 2 61825-94-3 43805 6857599 5310940 9887054

Interventional clinical trials:

(show top 50) (show all 130)
# Name Status NCT ID Phase Drugs
1 A Study to Evaluate the Safety and Efficacy of Lenvatinib in Participants With Refractory Differentiated Thyroid Cancer Recruiting NCT03573960 Phase 4 Lenvatinib
2 Levothyroxine Replacement With Liquid Gel Capsules vs Tablets Post-thyroidectomy Recruiting NCT02946918 Phase 4 Levothyroxine
3 Medico-Economic Comparison of Four Strategies of Radioiodine Ablation in Thyroid Carcinoma Patients Unknown status NCT00435851 Phase 3 Thyrogen, thyroid hormone withdrawal, iode 131
4 Multicenter Study Differentiated Thyroid Carcinoma Completed NCT00144079 Phase 3
5 Nexavar® Versus Placebo in Locally Advanced/Metastatic RAI-Refractory Differentiated Thyroid Cancer Completed NCT00984282 Phase 3 Sorafenib (Nexavar, BAY43-9006);Placebo
6 A New Study to Follow-up Thyroid Cancer Patients Who Participated in a Previous Study, Which Compared the Success of Destruction of the Thyroid Remnant Using Standard Treatment or Thyrogen. Completed NCT00295763 Phase 3 Thyrogen (thyrotropin alfa for injection)
7 The Usefulness of Staining Lymph Nodes During Operations for Cancer Thyroid in Detecting the Nodes That Have Cancer Completed NCT00794053 Phase 3
8 Comparison of the Safety and Successful Ablation of Thyroid Remnant in Post-thyroidectomized Euthyroid Patients (i.e. Patients Administered Thyrogen) Versus Hypothyroid Patients (no Thyrogen) Following 131I Administration Completed NCT00196729 Phase 3 Thyrogen + Radioiodine (131I)
9 Study of Anlotinib in Patients With Differentiated Thyroid Cancer(ALTER01032) Recruiting NCT02586337 Phase 2, Phase 3 Anlotinib;Placebo
10 Efficacy of Apatinib in Radioactive Iodine-refractory Differentiated Thyroid Cancer Recruiting NCT03048877 Phase 3 Apatinib Oral Tablet;Placebo Oral Tablet
11 A Trial of Lenvatinib (E7080) in Radioiodine (131 I)-Refractory Differentiated Thyroid Cancer in China Recruiting NCT02966093 Phase 3 Lenvatinib;Placebo
12 Donafenib in 131I-Refractory Differentiated Thyroid Cancer Recruiting NCT03602495 Phase 3 Donafenib;Placebo
13 A Study of Cabozantinib Compared With Placebo in Subjects With Radioiodine-refractory Differentiated Thyroid Cancer Who Have Progressed After Prior VEGFR-targeted Therapy Recruiting NCT03690388 Phase 3 Cabozantinib;Placebo
14 Differentiated Thyroid Cancer: is There a Need for Radioiodine Ablation in Low Risk Patients? Recruiting NCT01837745 Phase 3 rhTSH stimulation;I131
15 IoN- Is Ablative Radio-iodine Necessary for Low Risk Differentiated Thyroid Cancer Patients Recruiting NCT01398085 Phase 2, Phase 3
16 Comparing Complete Remission After Treatment With Selumetinib/Placebo in Patient With Differentiated Thyroid Cancer Active, not recruiting NCT01843062 Phase 3 Selumetinib;Placebo;Radioactive Iodine Therapy
17 Evaluation of Efficacy, Safety of Vandetanib in Patients With Differentiated Thyroid Cancer Active, not recruiting NCT01876784 Phase 3 Vandetanib (SAR390530);Placebo
18 Minimize Radioactive Iodine Ablation Of Remnant Thyroid in Differentiated Thyroid Cancer Active, not recruiting NCT02418247 Phase 2, Phase 3 I131;I123
19 A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Lenvatinib (E7080) in 131I-Refractory Differentiated Thyroid Cancer (DTC) Active, not recruiting NCT01321554 Phase 3 Lenvatinib;Placebo;Lenvatinib
20 High Dose vs Low Dose I 131 +/- rhTSH for Differentiated Thyroid Cancer Active, not recruiting NCT00415233 Phase 3
21 ESTIMation of the ABiLity of Prophylactic Central Compartment Neck Dissection to Modify Outcomes in Low-risk Differentiated Thyroid Cancer Not yet recruiting NCT03570021 Phase 3
22 Study of Apatinib in Patients With Differentiated Thyroid Cancer Unknown status NCT02731352 Phase 2 Apatinib
23 A Multicenter Phase II Pilot Open Label Unknown status NCT01830504 Phase 2 BKM120
24 Rosiglitazone in Treating Patients With Locoregionally Extensive or Metastatic Thyroid Cancer Unknown status NCT00098852 Phase 2 rosiglitazone maleate
25 Redifferentiation Therapy Using Alpha Lipoic Acid in Thyroid Cancer Unknown status NCT01396733 Phase 2 alpha-lipoic acids
26 177Lutetium-DOTA-Octreotate Therapy in Somatostatin Receptor-Expressing Neuroendocrine Neoplasms Unknown status NCT01237457 Phase 2 177Lu-DOTATATE
27 Effect of Carum Carvi on Thyroid Hormones and TSH Level Unknown status NCT01471288 Phase 1, Phase 2 Carum Cravi;Placebo
28 Comparison DW-MRI vs FDG PET/CT in the Detection of Early Recurrence of Cervical Well-differentiated Thyroid Carcinoma Completed NCT02515084 Phase 2
29 Celecoxib in Treating Patients With Progressive Metastatic Differentiated Thyroid Cancer Completed NCT00061906 Phase 2 celecoxib
30 Sutent Adjunctive Treatment of Differentiated Thyroid Cancer Completed NCT00668811 Phase 2 SU011248, Sutent
31 Evaluating the Safety and Efficacy of Oral E7080 in Medullary and Iodine-131 Refractory, Unresectable Differentiated Thyroid Cancers, Stratified by Histology Completed NCT00784303 Phase 2 E7080
32 Study of Irofulven Plus Capecitabine in Patients With Advanced Thyroid Cancer Completed NCT00124527 Phase 2 Irofulven + capecitabine
33 Phase II Study of IMRT With SIB as Adjuvant Treatment for High Risk Resected Well-differentiated Thyroid Cancer. Completed NCT00279721 Phase 2
34 Study of External Beam Radiotherapy to Thyroid Carcinoma Completed NCT01173289 Phase 2
35 Trial of LBH589 in Metastatic Thyroid Cancer Completed NCT01013597 Phase 2 LBH589
36 Tanespimycin in Treating Patients With Inoperable Locoregionally Advanced or Metastatic Thyroid Cancer Completed NCT00118248 Phase 2 tanespimycin
37 Effect of Lithium Carbonate on Low-Dose Radioiodine Therapy in Early Thyroid Cancer Completed NCT00251316 Phase 2 Lithium Carbonate;Placebo
38 Cabozantinib-S-Malate in Treating Patients With Refractory Thyroid Cancer Completed NCT01811212 Phase 2 Cabozantinib S-malate
39 Safety and Efficacy of VB-111 in Subjects With Advanced Differentiated Thyroid Cancer Completed NCT01229865 Phase 2 VB-111
40 Sunitinib Malate in Treating Patients With Iodine-Refractory Recurrent or Metastatic Thyroid Cancer Completed NCT00519896 Phase 2 sunitinib malate
41 Sorafenib as Adjuvant to Radioiodine Therapy in Non-Medullary Thyroid Carcinoma Completed NCT00887107 Phase 2 Sorafenib (nexavar)
42 Phase II Trial of Sorafenib (Nexavar) in Patients With Advanced Thyroid Cancer Completed NCT00654238 Phase 2 sorafenib
43 Recombinant Thyrotropin PET-CT Fusion Scanning in Thyroid Cancer Completed NCT00181168 Phase 2 Euthyroid Group
44 A Phase II Trial of Valproic Acid in Patients With Advanced Thyroid Cancers of Follicular Cell Origin Completed NCT01182285 Phase 2 Valproic Acid;Liothyronine Sodium
45 Bortezomib in Treating Patients With Metastatic Thyroid Cancer That Did Not Respond to Radioactive Iodine Therapy Completed NCT00104871 Phase 2 Bortezomib
46 A Phase 2, Open-label Study of AMG 706 to Treat Subjects With Locally Advanced or Metastatic Thyroid Cancer Completed NCT00121628 Phase 2 AMG 706
47 Phase 2 Trial of Apatinib Mesylate in Locally Advanced/Metastatic Differentiated Thyroid Carcinoma Recruiting NCT03167385 Phase 2 Apatinib Mesylate
48 PLD Combined With Cisplatin in the Treatment of Advanced Poorly Differentiated Thyroid Carcinoma Recruiting NCT03387943 Phase 2 PLD;Cisplatin
49 A Phase II Trial of Cabozantinib for the Treatment of Radioiodine (RAI)-Refractory Differentiated Thyroid Carcinoma (DTC) in the First-line Setting Recruiting NCT02041260 Phase 2 Cabozantinib
50 Atezolizumab Combinations With Chemotherapy for Anaplastic and Poorly Differentiated Thyroid Carcinomas Recruiting NCT03181100 Phase 2 Nab-paclitaxel - INDUCTION COHORT;Paclitaxel - INDUCTION COHORT;Vemurafenib - COHORT 1;Cobimetinib - COHORT 1;Atezolizumab - COHORT 1;Bevacizumab - COHORT 3;Nab-paclitaxel - COHORT 4;Paclitaxel - COHORT 4;Cobimetinib - COHORT 2;Atezolizumab - COHORT 2;Atezolizumab - COHORT 3;Atezolizumab - COHORT 4

Search NIH Clinical Center for Differentiated Thyroid Carcinoma

Genetic Tests for Differentiated Thyroid Carcinoma

Anatomical Context for Differentiated Thyroid Carcinoma

MalaCards organs/tissues related to Differentiated Thyroid Carcinoma:

41
Thyroid, Bone, Lymph Node, Lung, Testes, Salivary Gland, Brain

Publications for Differentiated Thyroid Carcinoma

Articles related to Differentiated Thyroid Carcinoma:

(show top 50) (show all 1096)
# Title Authors Year
1
The optimal TSH level necessary for successful radioiodine ablation of differentiated thyroid carcinoma, as well as the time to reach this level, is a work in progress. ( 29594409 )
2018
2
Clinicopathological and Survival Outcomes of Well-Differentiated Thyroid Carcinoma Undergoing Dedifferentiation: A Retrospective Study from FUSCC. ( 29951093 )
2018
3
Prognosis of Differentiated Thyroid Carcinoma with Initial Distant Metastasis: A Multicenter Study in Korea. ( 29947184 )
2018
4
Thyroidectomy Practice After Implementation of the 2015 American Thyroid Association Guidelines on Surgical Options for Patients With Well-Differentiated Thyroid Carcinoma. ( 29596551 )
2018
5
Use of radioiodine-131 scan to measure influence of surgical discipline, practice, and volume on residual thyroid tissue after total thyroidectomy for differentiated thyroid carcinoma. ( 29756327 )
2018
6
PD-L1 and IDO1 Are Expressed in Poorly Differentiated Thyroid Carcinoma. ( 29372535 )
2018
7
The effect of chewing-gum on dose rate of salivary gland in differentiated thyroid carcinoma patients treated with radioiodine. ( 29696945 )
2018
8
Prognostic significance of gross extrathyroidal extension invading only strap muscles in differentiated thyroid carcinoma. ( 29663333 )
2018
9
Impact on testicular function of a single ablative activity of 3.7 GBq radioactive iodine for differentiated thyroid carcinoma. ( 29912343 )
2018
10
Exploration of treatment de-escalation opportunities for differentiated thyroid carcinoma. ( 29398325 )
2018
11
Prevalence of adverse pathological features in 1 to 4a88cm low-risk differentiated thyroid carcinoma. ( 29417654 )
2018
12
Differentiated thyroid carcinoma presentation may be more aggressive in children and adolescents than in young adults. ( 29343289 )
2018
13
The Predictive Values of Lesion Size, F-18 FDG Avidity and I-131 Avidity for the Clinical Outcome of I-131 Treatment in Patients with Metastatic Differentiated Thyroid Carcinoma Only in the Lung. ( 29662562 )
2018
14
CRABP1, C1QL1 and LCN2 are biomarkers of differentiated thyroid carcinoma, and predict extrathyroidal extension. ( 29321030 )
2018
15
Re: "A Follow-Up Strategy for Patients with Excellent Response to Initial Therapy for Differentiated Thyroid Carcinoma" by Jeon et al. (Thyroid 2018;28:187-192). ( 29583109 )
2018
16
Risk of recurrence in a homogeneously managed pT3-differentiated thyroid carcinoma population. ( 29445865 )
2018
17
Less is More: The Impact of Multidisciplinary Thyroid Conference on the Treatment of Well-Differentiated Thyroid Carcinoma. ( 29058064 )
2018
18
Thyroglobulin "Nonsecretor" Metastatic Poorly Differentiated Thyroid Carcinoma with Noniodine Concentrating Disease and Aggressive Clinical Course: A Clinical Case Series. ( 29962718 )
2018
19
Psychosocial development in survivors of childhood differentiated thyroid carcinoma: a cross-sectional study. ( 29254931 )
2018
20
Seemingly Harmless Differentiated Thyroid Carcinoma Presenting as Bone Metastasis. ( 29967702 )
2018
21
A Follow-Up Strategy for Patients with an Excellent Response to Initial Therapy for Differentiated Thyroid Carcinoma: Less Is Better. ( 29179642 )
2018
22
Disease Burden and Outcome in Pediatric and Young Adults with Concurrent Graves Disease and Differentiated Thyroid Carcinoma. ( 29788090 )
2018
23
Tertiary Care Experience of Sorafenib in the Treatment of Progressive Radioiodine-Refractory Differentiated Thyroid Carcinoma: A Korean Multicenter Study. ( 29350109 )
2018
24
Young age is associated with increased rates of residual and recurrent paediatric differentiated thyroid carcinoma. ( 29672887 )
2018
25
Adipokines and inflammation markers and risk of differentiated thyroid carcinoma: The EPIC study. ( 29168186 )
2018
26
Clinical Value of<sup>99m</sup>Tc-3PRGD2 SPECT/CT in Differentiated Thyroid Carcinoma with Negative<sup>131</sup>I Whole-Body Scan and Elevated Thyroglobulin Level. ( 29323252 )
2018
27
Management of Solitary Intracranial Metastases of Differentiated Thyroid Carcinoma: 11 Pathologically Confirmed Cases and Systematic Literature Review. ( 29317366 )
2018
28
Insulin Resistance Associated With Differentiated Thyroid Carcinoma: Penalized Conditional Logistic Regression Analysis of a Matched Case-Control Study Data. ( 29696038 )
2018
29
Correction to: Tertiary Care Experience of Sorafenib in the Treatment of Progressive Radioiodine-Refractory Differentiated Thyroid Carcinoma: A Korean Multicenter Study, by Kim M, Kim TH, Shin DY, Lim DJ, Kim EY, Kim WB, Chung JH, Shong YK, Kim BH, and Kim WG on behalf of Korean Thyroid Cancer Study Group (KTCSG). Thyroid 2018;28(3)340-348. DOI: 10.1089/thy.2017.0356. ( 29749906 )
2018
30
Primary reconstructive method for tracheal defect from invasion by differentiated thyroid carcinoma. ( 28522300 )
2018
31
<sup>18</sup>F-FDG PET/CT and ultrasonogrpahy in differentiated thyroid carcinoma patients with elevated serum levels of antithyroglobulin antibody, negative Tg and whole body <sup>131</sup>I scan. ( 29550843 )
2018
32
Determining patient selection tool and response predictor for outpatient 30 mCi radioiodine ablation dose in non-metastatic differentiated thyroid carcinoma: a Japanese perspective. ( 29343651 )
2018
33
Pilocarpine effect on dose rate of salivary gland in differentiated thyroid carcinoma patients treated with radioiodine. ( 29517578 )
2018
34
Impact of Patient Age and Histological Type on Radioactive Iodine Avidity of Recurrent Lesions of Differentiated Thyroid Carcinoma. ( 29688947 )
2018
35
Atypical Features Resembling Poorly Differentiated Thyroid Carcinoma Presenting Entirely within a Follicular Adenoma. ( 30112239 )
2018
36
Multicentre clinical evaluation of the new highly sensitive Elecsys® thyroglobulin II assay in patients with differentiated thyroid carcinoma. ( 28960391 )
2018
37
Management of the central compartment in differentiated thyroid carcinoma. ( 28964612 )
2018
38
Prognostic indicators of outcomes in patients with lung metastases from differentiated thyroid carcinoma during long-term follow-up. ( 28972676 )
2018
39
Maternal and obstetrical outcome in 35 cases of well-differentiated thyroid carcinoma during pregnancy. ( 28988434 )
2018
40
In vitro studies of DNA damage and repair mechanisms induced by BNCT in a poorly differentiated thyroid carcinoma cell line. ( 29453554 )
2018
41
Effects of iodine-131 radiotherapy on Th17/Tc17 and Treg/Th17 cells of patients with differentiated thyroid carcinoma. ( 29467858 )
2018
42
Evaluation of adequacy of levo-thyroxine dosage in patients with differentiated thyroid carcinoma: correlation between morning and afternoon TSH determination. ( 29476411 )
2018
43
Hybrid SPECT/CT Imaging in the Management of Differentiated Thyroid Carcinoma ( 29479949 )
2018
44
Racial disparities of differentiated thyroid carcinoma: clinical behavior, treatments, and long-term outcomes. ( 29506526 )
2018
45
Pretherapeutic 124I dosimetry reliably predicts intratherapeutic blood kinetics of 131I in patients with differentiated thyroid carcinoma receiving high therapeutic activities. ( 29517576 )
2018
46
A Matter of Controversy: Is Radioiodine Therapy Favorable in Differentiated Thyroid Carcinoma? ( 29748234 )
2018
47
Improving care of patients with low-risk differentiated thyroid carcinoma. ( 29768626 )
2018
48
Juglone-ascorbic acid synergy inhibits metastasis and induces apoptotic cell death in poorly differentiated thyroid carcinoma by perturbing SOD and catalase activities. ( 29992683 )
2018
49
Impact of Gender and Age on the Prognosis of Differentiated Thyroid Carcinoma: a Retrospective Analysis Based on SEER. ( 30014218 )
2018
50
Low trabecular bone score in postmenopausal women with differentiated thyroid carcinoma after long-term TSH suppressive therapy. ( 30014437 )
2018

Variations for Differentiated Thyroid Carcinoma

ClinVar genetic disease variations for Differentiated Thyroid Carcinoma:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 BRAF NM_004333.4(BRAF): c.1799T> A (p.Val600Glu) single nucleotide variant Pathogenic rs113488022 GRCh37 Chromosome 7, 140453136: 140453136
2 BRAF NM_004333.4(BRAF): c.1799T> A (p.Val600Glu) single nucleotide variant Pathogenic rs113488022 GRCh38 Chromosome 7, 140753336: 140753336
3 BRAF NM_004333.4(BRAF): c.1799T> A (p.Val600Glu) single nucleotide variant Pathogenic rs113488022 NCBI36 Chromosome 7, 140099605: 140099605

Expression for Differentiated Thyroid Carcinoma

Search GEO for disease gene expression data for Differentiated Thyroid Carcinoma.

Pathways for Differentiated Thyroid Carcinoma

Pathways related to Differentiated Thyroid Carcinoma according to GeneCards Suite gene sharing:

(show top 50) (show all 66)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.28 ALK BRAF HRAS KRAS NRAS NTRK1
2
Show member pathways
13.08 BRAF HRAS KRAS NRAS NTRK1 NTRK3
3
Show member pathways
13.06 ALK HRAS KRAS NRAS NTRK1 NTRK3
4
Show member pathways
12.89 BRAF HRAS KRAS NCOA4 NRAS
5
Show member pathways
12.88 BRAF HRAS KRAS NRAS NTRK1 NTRK3
6
Show member pathways
12.78 ALK BRAF HRAS KRAS NRAS
7 12.78 BRAF HRAS KRAS NRAS NTRK1
8
Show member pathways
12.72 BRAF HRAS KRAS LPAR4 NRAS NTRK1
9
Show member pathways
12.69 BRAF HRAS KRAS NRAS NTRK1 NTRK3
10 12.64 BRAF HRAS KRAS LPAR4 NRAS
11
Show member pathways
12.52 BRAF HRAS KRAS NRAS TRIM24
12
Show member pathways
12.51 BRAF HRAS KRAS NRAS
13
Show member pathways
12.5 BRAF HRAS KRAS NCOA4 NRAS NTRK1
14
Show member pathways
12.48 BRAF HRAS KRAS NRAS
15
Show member pathways
12.44 HRAS KRAS NRAS NTRK1 NTRK3
16
Show member pathways
12.43 BRAF HRAS KRAS NRAS
17
Show member pathways
12.42 BRAF HRAS KRAS NRAS
18
Show member pathways
12.41 HRAS KRAS LPAR4 NRAS
19
Show member pathways
12.39 BRAF HRAS KRAS NRAS
20
Show member pathways
12.35 BRAF HRAS KRAS NRAS
21
Show member pathways
12.3 BRAF HRAS KRAS NRAS
22 12.3 BRAF HRAS KRAS NRAS
23
Show member pathways
12.28 BRAF HRAS KRAS NRAS
24
Show member pathways
12.27 BRAF HRAS KRAS NRAS
25
Show member pathways
12.27 ALK BRAF HRAS KRAS NRAS NTRK1
26
Show member pathways
12.21 BRAF HRAS KRAS NRAS
27 12.19 BRAF HRAS KRAS NDUFA13
28
Show member pathways
12.18 BRAF HRAS KRAS NRAS
29
Show member pathways
12.17 HRAS KRAS NRAS TRIM24
30
Show member pathways
12.11 BRAF HRAS KRAS NRAS
31 12.1 HRAS KRAS NRAS NTRK1 NTRK3
32 12.08 BRAF HRAS KRAS NRAS
33
Show member pathways
12.07 BRAF HRAS KRAS NRAS NTRK1
34 12.04 ALK BRAF HRAS KRAS LPAR4 NCOA4
35
Show member pathways
12.03 BRAF HRAS KRAS NRAS NTRK1 NTRK3
36 12.01 BRAF HRAS KRAS NRAS
37 11.99 BRAF HRAS KRAS NRAS
38
Show member pathways
11.99 BRAF HRAS KRAS NRAS TRIM24
39 11.97 BRAF HRAS KRAS NRAS
40
Show member pathways
11.95 HRAS KRAS NRAS
41 11.9 HRAS KRAS NRAS
42
Show member pathways
11.87 HRAS KRAS NRAS
43
Show member pathways
11.85 HRAS KRAS NRAS TRIM24
44 11.84 HRAS KRAS NRAS
45
Show member pathways
11.79 BRAF HRAS KRAS NRAS
46 11.72 BRAF HRAS KRAS NRAS
47 11.71 BRAF HRAS PAX8
48 11.69 HRAS KRAS NRAS
49
Show member pathways
11.65 BRAF HRAS KRAS NRAS
50 11.64 BRAF HRAS KRAS NRAS NTRK1 NTRK3

GO Terms for Differentiated Thyroid Carcinoma

Biological processes related to Differentiated Thyroid Carcinoma according to GeneCards Suite gene sharing:

(show all 19)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of apoptotic process GO:0043066 9.97 ALK BRAF ERC1 NTRK1 NTRK3
2 positive regulation of gene expression GO:0010628 9.88 BRAF HRAS KRAS NTRK3 TRIM24
3 MAPK cascade GO:0000165 9.83 BRAF HRAS KRAS NRAS
4 transmembrane receptor protein tyrosine kinase signaling pathway GO:0007169 9.74 ALK NTRK1 NTRK3
5 ephrin receptor signaling pathway GO:0048013 9.72 HRAS NTRK1 NTRK3
6 regulation of protein stability GO:0031647 9.71 KRAS TPR TRIM24
7 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.71 ALK ERC1 KRAS NTRK1
8 Ras protein signal transduction GO:0007265 9.69 HRAS KRAS NRAS
9 stimulatory C-type lectin receptor signaling pathway GO:0002223 9.67 HRAS KRAS NRAS
10 negative regulation of neuron apoptotic process GO:0043524 9.67 BRAF HRAS KRAS NTRK1
11 positive regulation of phospholipase C activity GO:0010863 9.56 HRAS NTRK3
12 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.55 ALK BRAF HRAS NTRK1 NTRK3
13 cellular response to nerve growth factor stimulus GO:1990090 9.5 BRAF NTRK1 NTRK3
14 response to isolation stress GO:0035900 9.46 HRAS KRAS
15 mechanoreceptor differentiation GO:0042490 9.43 NTRK1 NTRK3
16 positive regulation of protein phosphorylation GO:0001934 9.35 ALK HRAS KRAS NTRK1 NTRK3
17 neurotrophin signaling pathway GO:0038179 9.26 NTRK1 NTRK3
18 peptidyl-tyrosine phosphorylation GO:0018108 9.02 ALK BRAF NTRK1 NTRK3 TRIM24
19 cell differentiation GO:0030154 10.06 ALK BRAF ETV6 NTRK1 NTRK3 PAX8

Molecular functions related to Differentiated Thyroid Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein kinase activity GO:0004672 9.77 ALK BRAF NTRK1 NTRK3 TRIM24
2 transmembrane receptor protein tyrosine kinase activity GO:0004714 9.43 ALK NTRK1 NTRK3
3 GPI-linked ephrin receptor activity GO:0005004 9.32 NTRK1 NTRK3
4 neurotrophin binding GO:0043121 9.16 NTRK1 NTRK3
5 protein tyrosine kinase activity GO:0004713 9.02 ALK BRAF NTRK1 NTRK3 TRIM24
6 neurotrophin receptor activity GO:0005030 8.96 NTRK1 NTRK3

Sources for Differentiated Thyroid Carcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....